|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pourhoseingholi MA, Vahedi M and
Baghestani AR: Burdenof gastrointestinal cancer in Asia; an
overview. Gastroenterol Hepatol Bed Bench. 8:19–27. 2015.PubMed/NCBI
|
|
3
|
Tänzer M, Liebl M and Quante M: Molecular
biomarkers in esophageal, gastric, and colorectal adenocarcinoma.
Pharmacol Ther. 140:133–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liang H and Kim YH: Identifying molecular
drivers of gastric cancer through next-generation sequencing.
Cancer Lett. 340:241–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
González CA and Agudo A: Carcinogenesis,
prevention and early detection of gastric cancer: Where we are and
where we should go. Int J Cancer. 130:745–753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yared JA and Tkaczuk KH: Update on taxane
development: New analogs and new formulations. Drug Des Devel Ther.
6:371–384. 2012.PubMed/NCBI
|
|
7
|
Bu XF, Zhang J, Jia LJ, Liang B, Zhang J,
Liu Y and Yan YL: Effect of human interferon-λ1 recombinant
adenovirus on a gastric cancer orthotopic transplantation model.
Exp Ther Med. 8:1115–1122. 2014.PubMed/NCBI
|
|
8
|
Gao Z, Zhu M, Wu Y, Gao P, Qin Z and Wang
H: Interferon-λ1 induces G1 phase cell cycle arrest and apoptosis
in gastric carcinoma cells in vitro. Oncol Rep. 32:199–204.
2014.PubMed/NCBI
|
|
9
|
Ferrantini M, Capone I and Belardelli F:
Interferon-α and cancer: Mechanisms of action and new perspectives
of clinical use. Biochimie. 89:884–893. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hui X, Chen H, Zhang S, Ma X, Wang X and
Huang B: Antitumor activities of recombinant human interferon
(IFN)-λ1 in vitro and in xenograft models in vivo for
colon cancer. Cancer Lett. 311:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan Y, Zhang J, Liu Y, Zhu T, Yuan L, Ge
Y, Ding H and Bu X: Inhibition of lung adenocarcinoma transfected
with interleukin 28A recombinant adenovirus (Ad-mIFN-λ2) in
vivo. Cancer Biother Radiopharm. 28:124–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lopušná K, Režuchová I, Betáková T, et al:
Interferons lambda, new cytokines with antiviral activity. Acta
Virol. 57:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steen HC and Gamero AM: Interferon-lambda
as a potential therapeutic agent in cancer treatment. J Interferon
Cytokine Res. 30:597–602. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donnelly RP and Kotenko SV:
Interferon-lambda: A new addition to an old family. J Interferon
Cytokine Res. 30:555–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meager A, Visvalingam K, Dilger P, Bryan D
and Wadhwa M: Biological activity of interleukins −28 and −29:
Comparison with type I interferons. Cytokine. 31:109–118. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dumoutier L, Tounsi A, Michiels T,
Sommereyns C, Kotenko SV and Renauld JC: Role of the interleukin
(IL)-28 receptor tyrosine residues for antiviral and
antiproliferative activity of IL-29/interferon-λ1: Similarities
with type I interferon signaling. J Biol Chem. 279:32269–32274.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lasfar A, Lewis-Antes A, Smirnov SV,
Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F,
Donnelly RP, et al: Characterization of the mouse IFN-lambdas
ligand-receptor system: IFN-λs exhibit antitumor activity against
B16 melanoma. Cancer Res. 66:4468–4477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khalighinejad N, Hariri H, Behnamfar O,
Yousefi A and Momeni A: Adenoviral gene therapy in gastric cancer:
A review. World J Gastroenterol. 14:180–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rincon MY, VandenDriessche T and Chuah MK:
Gene therapy for cardiovascular disease: Advances in vector
development, targeting, and delivery for clinical translation.
Cardiovasc Res. 108:4–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang I and Huang I: Adenovirus technology
for gene manipulation and functional studies. Drug Discov Today.
5:10–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Büning H, Huber A, Zhang L, Meumann N and
Hacker U: Engineering the AAV capsid to optimize
vector-host-interactions. Curr Opin Pharmacol. 24:94–104. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Q, Kawamura K, Okamoto S, Fujie H,
Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H and Tagawa M:
Adenoviruses-mediated transduction of human oesophageal carcinoma
cells with the interferon-λ genes produced anti-tumour effects. Br
J Cancer. 105:1302–1312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelly C, Klenerman P and Barnes E:
Interferon-lambdas: The next cytokine storm. Gut. 60:1284–1293.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tagawa M, Kawamura K, Li Q, Tada Y,
Hiroshima K and Shimada H: A possible anticancer agent, type III
interferon, activates cell death pathways and produces antitumor
effects. Clin Dev Immunol. 2011:4790132011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato A, Ohtsuki M, Hata M, Kobayashi E and
Murakami T: Antitumor activity of IFN-λ in murine tumor models. J
Immunol. 176:7686–7694. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maher SG, Sheikh F, Scarzello AJ,
Romero-Weaver AL, Baker DP, Donnelly RP and Gamero AM: IFNalpha and
IFNlambda differ in their antiproliferative effects and duration of
JAK/STAT signaling activity. Cancer Biol Ther. 7:1109–1115. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li M, Liu X, Zhou Y and Su SB:
Interferon-lambdas: The modulators of antivirus, antitumor, and
immune responses. J Leukoc Biol. 86:23–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Lewis-Antes A, Huang J, Balan M and
Kotenko SV: Regulation of apoptosis by type III interferons. Cell
Prolif. 41:960–979. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Kawamura K, Tada Y, Shimada H,
Hiroshima K and Tagawa M: Novel type III interferons produce
anti-tumor effects through multiple functions. Front Biosci
(Landmark Ed). 18:909–918. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Woehlecke H, Pohl A, Alder-Baerens N, Lage
H and Herrmann A: Enhanced exposure of phosphatidylserine in human
gastric carcinoma cells overexpressing the half-size ABC
transporter BCRP (ABCG2). Biochem J. 376:489–495. 2003. View Article : Google Scholar : PubMed/NCBI
|
